67P Survival of responders to nivolumab (NIVO) + ipilimumab (IPI) as first-line treatment for advanced NSCLC in CheckMate 227, part 1

Authors :: P. Sun
Pamela Salman
S.-B. Kim
M. Schenker
Helena Linardou
E. De La Mora Jimenez
Fabrice Barlesi
Clarisse Audigier-Valette
Ang Li
Kynan Feeney
Matthew D. Hellmann
Istvan Albert
T-E. Ciuleanu
Gregory A. Otterson
Julie R. Brahmer
Samreen Ahmed
Krzysztof Lesniewski-Kmak
Norbert Frickhofen
B. Zurawski
Source :: Annals of Oncology. 31:S1444-S1445
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: Oncology
First line treatment
medicine.medical_specialty
business.industry
Internal medicine
medicine
Checkmate
Ipilimumab
Hematology
Nivolumab
business
medicine.drug

Full Text Access

Tools